Orgenesis Inc. Long Term Debt (Total)

Long Term Debt (Total) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending June 29, 2021 was $5.5 Million (a -31.54% decrease compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) decreased by -51.09%
  • Annual Long Term Debt (Total) for 2020 was $8.28 Million (a -34.24% decrease from previous year)
  • Annual Long Term Debt (Total) for 2019 was $12.6 Million (a 366.59% increase from previous year)
  • Annual Long Term Debt (Total) for 2018 was $2.7 Million (a 0.0% decrease from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of Orgenesis Inc.

Most recent Long Term Debt (Total)of ORGS including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of Orgenesis Inc.

Orgenesis Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $5.5 $8.03
2020 $8.28 $11.24 $10.7 $10.85 $8.28
2019 $12.14 $10.25 $10.34 $3.39 $12.6
2018 $3.34 $1.8 $1.9 $2.57 $2.7
2017 $4.53 $4.84 $5.06 $4.53
2016 $4.34 $4.35 $3.29 $4.35
2015 $2.54 $2.54

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.